Synapse - William Tap

Results (375)

Platelet-derived growth factor receptor alpha promotes cancer stem-like cell phenotypes in sarcomas including metastasis and chemotherapy resistance

Meeting Abstract

Chang, K. K.; Yoon, C.; Tap, W. D.; Yoon, S. S.
Journal of the American College of Surgeons (2016)

Fulltext@MSK | Save

Chronic imatinib (> 3 years) therapy after complete resection of primary, high-risk gastrointestinal stromal tumor (GIST) is associated with low recurrence

Meeting Abstract

Cavnar, M. J.; Balachandran, V. P.; Chi, P.; Keohan, M. L.; Tap, W. D.; DeMatteo, R. P.
Journal of the American College of Surgeons (2016)

Fulltext@MSK | Save

A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (pdgfrα) monoclonal antibody, in advanced soft tissue sarcoma (sts)

Meeting Abstract

Tap, W.; Jones, R. L.; Chmielowski, B.; Elias, A. D.; Adkins, D.; Van Tine, B. A.; Agulnik, M.; Cooney, M.; Livingston, M. B.; Pennock, G.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021

Meeting Abstract

Tap, W.; Papai, Z.; van Tine, B.; Attia, S.; Ganjoo, K.; Jones, R. L.; Schuetze, S.; Reed, D.; Chawla, S. P.; Riedel, R.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Exposure-response of olaratumab for survival outcomes and safety when combined with doxorubicin in soft tissue sarcoma (STS) patients

Meeting Abstract

Jones, R.; Mo, G.; Baldwin, J. R.; Nichols, R. D.; Ilaria, R. L.; Conti, I.; Cronier, D. M.; Tap, W. D.
Annals of Oncology (2016)

Fulltext@MSK | Save

Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial